Literature DB >> 9779389

Hospital-acquired pneumonia: epidemiology, etiology, and treatment.

R McEachern1, G D Campbell.   

Abstract

Despite improvements in diagnosis, treatment, and prevention, hospital-acquired pneumonia (HAP) remains the number one cause of nosocomial mortality. This article reviews the current knowledge regarding the incidence, epidemiology, and causes of HAP, with the appreciation that the available information is incomplete and that controversies are common, and thus the authors provide a rational approach to the initial management of HAP in immunocompetent adults. A discussion of therapy and what to do with patients who do not respond to the empiric therapy are included. The American Thoracic Society (ATS) statement on HAP has served as a foundation for this review but has been supplemented by newer literature that was not available when the ATS statement was developed.

Entities:  

Mesh:

Year:  1998        PMID: 9779389     DOI: 10.1016/s0891-5520(05)70209-9

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  15 in total

1.  Swept under the carpet? The role of mucociliary clearance in ventilator-induced lung injury.

Authors:  Cory M Yamashita; Ruud A W Veldhuizen
Journal:  Intensive Care Med       Date:  2010-10-28       Impact factor: 17.440

2.  Ventilator-associated pneumonia: diagnosis, treatment, and prevention.

Authors:  Steven M Koenig; Jonathon D Truwit
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

Review 3.  Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

Authors:  Brad Spellberg; George Talbot
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

4.  Aerobic Gram-negative Bacillary Pneumonia.

Authors:  Stephen Parodi; Matthew Bidwell Goetz
Journal:  Curr Infect Dis Rep       Date:  2002-06       Impact factor: 3.725

5.  Gamma interferon does not enhance clearance of Pseudomonas aeruginosa but does amplify a proinflammatory response in a murine model of postseptic immunosuppression.

Authors:  E D Murphey; David N Herndon; Edward R Sherwood
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

6.  In-patient rehabilitation outcomes following lower extremity fracture in patients with pneumonia.

Authors:  Ijaz Ahmed; James E Graham; Amol M Karmarkar; Carl V Granger; Kenneth J Ottenbacher
Journal:  Respir Care       Date:  2013-04       Impact factor: 2.258

Review 7.  New developments in antibacterial choice for lower respiratory tract infections in elderly patients.

Authors:  Anna Maria Ferrara; Anna Maria Fietta
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 8.  Vaccines for Pseudomonas aeruginosa: a long and winding road.

Authors:  Gregory P Priebe; Joanna B Goldberg
Journal:  Expert Rev Vaccines       Date:  2014-02-27       Impact factor: 5.217

9.  A 7-year study of severe hospital-acquired pneumonia requiring ICU admission.

Authors:  Jordi Vallés; Eduard Mesalles; Dolors Mariscal; Ma del Mar Fernández; Rocío Peña; José Luis Jiménez; Jordi Rello
Journal:  Intensive Care Med       Date:  2003-09-10       Impact factor: 17.440

10.  Noninvasive ventilation for patients near the end of life: what do we know and what do we need to know?

Authors:  William J Ehlenbach; J Randall Curtis
Journal:  Crit Care Med       Date:  2008-03       Impact factor: 7.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.